Recent Updates
Recently added Catalysts
FATE

Emerging Data with FT819: Favorable Tolerability and Clinical Activity in Systemic Sclerosis Using Off-the-Shelf, iPSC-Derived Anti-CD19 CAR T cells without Fludarabine

Key Takeaway: The article discusses the use of FT819, an iPSC-derived anti-CD19 CAR T cell therapy, in treating systemic sclerosis. It highlights favorable tolerability and clinical activity, although specific data and results are not provided in the text. The focus is on the innovative approach of using off-the-shelf CAR T cells without fludarabine.
Price reaction · baseline $2.93 (2026-07-08 close) · hit pre-market · 1 other FATE headline(s) in the window, move may be shared
day 0 close · peak
+6.1%
day 1
+5.8%
day 3
+2%

Market Sentiment Analysis

Full Press Release Details

• Privacy Overview
• Strictly Necessary Cookies
• 3rd Party Cookies
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognizing you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
For more information about the data we collect please visit our Privacy Policy .
Strictly Necessary Cookies is enabled at all times so that we can save your preferences for cookie settings.
This website uses Google Analytics to collect information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.
Last updated: Jul 9, 2026